Sanofi-Synthelabo Recherche Selects Tripos for Drug Discovery Partnership
Tripos, Inc. announced that it has entered a strategic partnership with Sanofi-Synthelabo Recherche, an affiliate of Sanofi-Aventis.
Sanofi-Synthelabo Recherche has identified a number of proprietary chemistry motifs that exhibit therapeutic potential in a wide range of target areas. Tripos will employ its knowledge-driven chemistry approach to design and synthesize compounds that expand these areas. Tripos' high-throughput medicinal chemistry process will enable the rapid synthesis of those compounds to meet Sanofi-Synthelabo Recherche's project time frame requirements.
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.